HUP0300133A2 - Amphiphilic polymers and polypeptide conjugates comprising same - Google Patents

Amphiphilic polymers and polypeptide conjugates comprising same

Info

Publication number
HUP0300133A2
HUP0300133A2 HU0300133A HUP0300133A HUP0300133A2 HU P0300133 A2 HUP0300133 A2 HU P0300133A2 HU 0300133 A HU0300133 A HU 0300133A HU P0300133 A HUP0300133 A HU P0300133A HU P0300133 A2 HUP0300133 A2 HU P0300133A2
Authority
HU
Hungary
Prior art keywords
same
amphiphilic polymers
peptides
polypeptide conjugates
proteins
Prior art date
Application number
HU0300133A
Other languages
English (en)
Hungarian (hu)
Inventor
Nnochiri N Ekwuribe
Original Assignee
Nobex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobex Corp filed Critical Nobex Corp
Publication of HUP0300133A2 publication Critical patent/HUP0300133A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
HU0300133A 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same HUP0300133A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/459,443 US6638906B1 (en) 1999-12-13 1999-12-13 Amphiphilic polymers and polypeptide conjugates comprising same
PCT/US2000/033592 WO2001041812A2 (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same

Publications (1)

Publication Number Publication Date
HUP0300133A2 true HUP0300133A2 (en) 2003-05-28

Family

ID=23824795

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300133A HUP0300133A2 (en) 1999-12-13 2000-12-11 Amphiphilic polymers and polypeptide conjugates comprising same

Country Status (18)

Country Link
US (2) US6638906B1 (US06638906-20031028-C00029.png)
EP (1) EP1237580A2 (US06638906-20031028-C00029.png)
JP (1) JP2003516366A (US06638906-20031028-C00029.png)
KR (1) KR20020068053A (US06638906-20031028-C00029.png)
CN (1) CN1434725A (US06638906-20031028-C00029.png)
AU (1) AU2087501A (US06638906-20031028-C00029.png)
BR (1) BR0016339A (US06638906-20031028-C00029.png)
CA (1) CA2394928A1 (US06638906-20031028-C00029.png)
CZ (1) CZ20021990A3 (US06638906-20031028-C00029.png)
HK (1) HK1049283A1 (US06638906-20031028-C00029.png)
HU (1) HUP0300133A2 (US06638906-20031028-C00029.png)
IL (1) IL150119A0 (US06638906-20031028-C00029.png)
MX (1) MXPA02005885A (US06638906-20031028-C00029.png)
NO (1) NO20022793L (US06638906-20031028-C00029.png)
PL (1) PL359174A1 (US06638906-20031028-C00029.png)
RU (1) RU2002118709A (US06638906-20031028-C00029.png)
WO (1) WO2001041812A2 (US06638906-20031028-C00029.png)
ZA (1) ZA200204603B (US06638906-20031028-C00029.png)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425138D0 (en) 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1468116A2 (en) 2002-01-16 2004-10-20 Dynal Biotech ASA Method for isolating nucleic acids and protein from a single sample
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1569683B1 (en) * 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
GB0229287D0 (en) * 2002-12-16 2003-01-22 Dna Res Innovations Ltd Polyfunctional reagents
CN1761680A (zh) 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CA2544156C (en) * 2003-10-29 2012-07-10 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
AU2005257484A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US8329958B2 (en) 2004-07-02 2012-12-11 Biocon Limited Combinatorial synthesis of PEG oligomer libraries
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
CA2606270A1 (en) * 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
US20070026383A1 (en) * 2005-07-15 2007-02-01 Quintessence Biosciences, Inc. Methods and compositions for extracting membrane proteins
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
PT2314609T (pt) * 2008-07-30 2017-03-06 Takeda Pharmaceuticals Co Derivado de metastina e sua utilização
MX2013009859A (es) 2011-03-01 2014-02-28 Novo Nordisk As Ligandos dr3 antagonicos.
CN103740659B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
CN103740661B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
US20140039158A1 (en) * 2012-07-25 2014-02-06 Belrose Pharma, Inc. Polymeric conjugates and methods of preparing the same
CN106729735B (zh) * 2017-03-09 2020-05-12 国家纳米科学中心 一种pH敏感的多肽聚合物及其制备方法和应用
BR112020021134A2 (pt) * 2018-04-16 2021-03-23 Merck Patent Gmbh aditivos para formulações de proteínas para aprimorar estabilidade térmica
KR20240026573A (ko) * 2022-08-22 2024-02-29 부산대학교 산학협력단 폴리소르베이트-숙신산-카르니틴 복합체 및 이를 포함하는 생리활성 물질 또는 약물 전달용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP0862631A1 (en) 1995-10-26 1998-09-09 The Board Of Regents, The University Of Texas System Luminal cholecystokinin-releasing factor
JP3737518B2 (ja) 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー, エル.ピー. 水溶性パクリタキセルプロドラッグ
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Also Published As

Publication number Publication date
CN1434725A (zh) 2003-08-06
RU2002118709A (ru) 2004-02-27
HK1049283A1 (zh) 2003-05-09
KR20020068053A (ko) 2002-08-24
BR0016339A (pt) 2002-08-27
NO20022793D0 (no) 2002-06-12
WO2001041812A3 (en) 2002-03-21
CZ20021990A3 (cs) 2002-11-13
US20040092449A1 (en) 2004-05-13
IL150119A0 (en) 2002-12-01
JP2003516366A (ja) 2003-05-13
EP1237580A2 (en) 2002-09-11
NO20022793L (no) 2002-08-13
PL359174A1 (en) 2004-08-23
CA2394928A1 (en) 2001-06-14
ZA200204603B (en) 2003-11-26
US6638906B1 (en) 2003-10-28
MXPA02005885A (es) 2002-10-23
AU2087501A (en) 2001-06-18
WO2001041812A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
HUP0300133A2 (en) Amphiphilic polymers and polypeptide conjugates comprising same
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
ATE252601T1 (de) Lang wirkende insulinotrope peptide
EP2112161A3 (en) Peptides that lower blood glucose levels
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
PT1144459E (pt) Acidos hialuronicos reticulados e as suas utilizacoes em medicina
CA2174325A1 (en) Non-antigenic branched polymer conjugates
NO962088L (no) Preparat for in vivo-produksjon av terapeutiske produkter
WO2002051390A3 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
HUP0400466A2 (hu) G-CSF konjugátumok
HK1043801A1 (zh) 精確長度的聚酰胺鏈、其製備方法和其與蛋白質的綴合物
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
ATE338771T1 (de) Antagonisten des intestinotrophen glp-2 peptides
AU2002365360A1 (en) Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
AU2003286404A8 (en) Peptide nanostructures, methods for their preparation and use
AU777185C (en) Pharmaceutical form of administration for peptides, methods for its production and use
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
WO2002044197A3 (en) Cytokine receptor binding peptides
EP1608408A4 (en) BIOLOGICALLY ACTIVE MATERIAL CONJUGATED WITH BIOCOMPATIBLE POLYMER WITH 1: 1 COMPLEX, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
CA2373252A1 (en) Long lasting anti-angiogenic peptides
WO2001036656A3 (en) A complex between hyaluronic acid and a biomolecule and its use
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
HUP0201696A2 (en) Cyclic peptides, pharmaceutical compositions comprising thereof and their use
MY138219A (en) Biologically active peptides
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao